** Hong Kong-listed shares of Chinese biopharma group Zai
Lab Ltd 9688.HK soar as much as 46.8% to HK$40, their biggest
daily pct rise since debut in September 2020
** Stock tracks a 41.8% jump in U.S.-listed shares ZLAB.O
on Thursday, on positive data from a late-stage study of cancer
therapy by partner Novocure NVCR.O urn:newsml:reuters.com:*:nL4N33Q2MU
** Hong Kong shares hit the highest since Sept 15; biggest
pct gainer in Hang Seng Composite Index .HSCI and on the Hong
Kong bourse
** Shanghai-based company said on Friday it obtained an
exclusive license from NovoCure to develop and commercialize
Tumor Treating Fields in mainland China, Hong Kong Macau and
Taiwan
** The Hang Seng Commerce & Industry Index .HSNC gains
0.2% and the healthcare index .HSCIH rises 0.5%
** The Hang Seng Composite Index .HSCI climbs 0.3% and the
Hang Seng Index .HSI up 0.2%
(Reporting by Donny Kwok)
((donny.kwok@thomsonreuters.com))